Pretargeting: Bridging the Two Worlds of Radiopharmaceutical Probes.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40293376.
- Also identified by DOI 10.1158/1078-0432.CCR-25-0568 and PMC identifier 12209817.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The human trophoblast cell-surface antigen 2 is expressed in a variety of malignant diseases. Using pretargeting methodology, a novel antibody against trophoblast cell-surface antigen 2 was radiolabeled and evaluated in a preclinical setting. This showed promising characteristics, lending itself as a potential basis for further clinical trials as an imaging agent and a potential theranostic. See related article by Pratt et al., p. 2719.
Medical subject headings
- Radiopharmaceuticals
- Neoplasms
- Antibodies, Monoclonal